Alivus Life Sciences Ltd
Alivus Life Sciences Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Non-GPL business is already growing at double-digit; expected to continue outpacing GPL business. The company aims for sustained profitable growth by focusing on unique, high-entry-barrier products, fostering differentiation and sustainable margins.
From Alivus Life Sciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Non-GPL business is already growing at double-digit; expected to continue outpacing GPL business.
- Overall sales volume growth across segments is significant and expected to persist.
- New product launches contribute to growth, though not yet a major revenue driver.
- Capacity expansions (Solapur greenfield, brownfield expansions at Ankleshwar and Dahej) will enable volume and revenue growth post ramp-up.
- Solapur Phase 1 expected to start with 40-50% utilization, scaling to 60-70% gradually.
- New launches and pipeline buildup (especially complex molecules and high-potent APIs) underpin medium- to long-term growth.
- CDMO business ramping up with new projects commencing, supporting future revenue momentum.
- Balanced geographic diversification (India, Europe, Latin America, US, Japan) aids steady growth.
- Focus remains on profitable, high-quality growth rather than volume at cost of margins.
Profitability & Margins
See what Alivus Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY27 capex planned at about INR 540 crores, including carryover from FY26 and fresh investments.
- Entire capex funded through internal accruals.
- Investments focus on building new capabilities at Solapur (greenfield project) and strengthening the R&D platform.
- Capacity expansion to increase from 1,198 KL in FY24 to a planned 2,690 KL by FY28.
- Solapur facility: Phase 1 includes 370 KL for BI block and 120 KL for API block, with 40-50% initial utilization.
- Brownfield expansions at Ankleshwar and Dahej, with rapid ramp-up expected within 2-3 quarters.
- Solapur has land bank for additional 700-800 KL capacity, offering runway for 3-4 years.
- R&D spend expected to rise to about 4% of sales over the next 1-2 years and then stabilize.
- Focus areas: flow chemistry, high potent APIs, pellets and granules, and lateral expansion of the API portfolio.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alivus Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Alivus Life Sciences operates primarily on long-term contracts in its CDMO business.
- In the generic API segment, contracts are fewer and typically short-term, lasting about 1-2 years.
- The company prefers short to medium-term contracts to maintain flexibility due to a dynamic environment.
- This flexibility helps them respond to market changes, such as price increases related to external factors (e.g., war situations).
- Orders are generally placed by customers as needed, without getting locked into cumbersome clauses.
- No specific figures on current or expected orderbook/pending orders were disclosed in the transcript.
Alivus Life Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹689 Cr, net profit ₹163 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alivus Life Sciences Ltd's management said in earlier quarters
- Q2 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
- Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
- RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
- Sai Parenterals Ltd (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…
Frequently Asked Questions
What were Alivus Life Sciences Ltd Q4 FY26 results?
Non-GPL business is already growing at double-digit; expected to continue outpacing GPL business. The company aims for sustained profitable growth by focusing on unique, high-entry-barrier products, fostering differentiation and sustainable margins.
What is Alivus Life Sciences Ltd share price analysis?
Alivus Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 26.3 with a market cap of ₹16,341 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alivus Life Sciences Ltd planning capital expenditure?
FY27 capex planned at about INR 540 crores, including carryover from FY26 and fresh investments.
Keep Alivus Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.